10 citations
,
January 2012 in “Case reports in medicine” This report describes two cases where patients developed vitiligo as a side effect of diphencyprone treatment for alopecia areata, highlighting the need to inform patients about this potential adverse effect.
1 citations
,
September 2025 in “JEADV Clinical Practice” This review highlights the need for inclusive dermatology practices to address variations in skin conditions globally by incorporating tools like AI, teledermatology, and culturally competent education.
20 citations
,
November 2017 in “JAAD case reports” This case report describes a patient with psoriasis, vitiligo, and alopecia areata who showed significant improvement in all conditions after treatment with ustekinumab, suggesting potential benefits of IL-12/23 blockade for these autoimmune diseases.
4 citations
,
January 2019 in “Micron” This study observed that fetal hair follicle melanocytes varied in morphology and development stages, with melanosomes undergoing degradation into irregular pigment particles within keratinocytes.
July 2026 in “Journal of Investigative Dermatology” Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.
36 citations
,
January 2010 in “International Journal of Trichology” Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.
4 citations
,
October 2019 in “Skin Appendage Disorders” This case report describes the first known instance of hair and eyebrow hyperpigmentation in a patient after seven months of gefitinib treatment for non-small cell lung cancer.
3 citations
,
December 2024 in “International Journal of Dermatology” This review examined the psychological effects, mechanisms, health associations, and treatments related to premature hair graying, highlighting factors like genetics, oxidative stress, smoking, and diet, with the aim of enhancing understanding and addressing its broader implications.
2 citations
,
November 2024 in “JAAD reviews.” This review reported that certain systemic drugs, including antiepileptics and anticancer drugs, can lead to changes in hair pigmentation, such as hypopigmentation or hyperpigmentation, with varied prevalence and clinical characteristics.
March 2026 in “The American Journal of Managed Care” The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” This report discusses the Ninth World Congress for Hair Research and highlights the potential of hair follicle studies to advance understanding of various diseases, with no new clinical results presented.
March 2022 in “Wound practice & research” This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.
This article explores the potential applications of polyglutamic acid in cosmetics, discussing its benefits for skincare and haircare, but reports no new experimental results.
January 2025 in “Skin Health and Disease” In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.
42 citations
,
August 2013 in “International Journal of Women's Health” This review discusses the current therapeutic options for female pattern hair loss and emphasizes the need for managing patient expectations of permanent regrowth, reporting no new clinical results.
January 2024 in “Dermatologic therapy” This review describes the characteristics and treatment of acne keloidalis nuchae, focusing on related conditions and available therapeutic approaches, but presents no new clinical findings.
277 citations
,
December 2019 in “Frontiers in Immunology” This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.
25 citations
,
January 2024 in “Journal of Lipids” This review reports that cubosomes, used as drug nanocarriers in topical treatments, offer potential benefits for managing skin and eye diseases by improving bioadhesion, retention, and sustained release compared to conventional formulations, but also face manufacturing and biological challenges for effective clinical outcomes.
5 citations
,
February 2022 in “Acta Biomaterialia” This review highlights the potential of nanotechnology-based formulations in hair care and treatment, emphasizing how these innovative materials can enhance the stability, efficacy, and safety of active compounds while addressing the limitations of conventional formulations.
April 2026 in “Cosmetics” In this review, several studies on Astragalus species, particularly Astragalus membranaceus, highlight their skin rejuvenating, photoprotective, antimicrobial, and wound-healing properties, though the authors note limitations due to reliance on non-human studies and short trial durations.
October 2025 in “Pharmaceutics” This study highlights the clinical potential of microneedles as an innovative transdermal drug delivery system for treating various skin diseases with minimal pain and high patient compliance.
June 2025 in “Cell Regeneration” In this study, Dguok deficiency in mice led to premature hair greying due to a loss of melanocyte stem cells and mature melanocytes, with increased oxidative stress and cell death; treatment with an antioxidant mitigated these effects, suggesting DGUOK's importance in hair pigmentation maintenance.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” This study found that immune privilege is preserved in hair follicles of nonsegmental vitiligo patients compared to those with alopecia areata, potentially protecting follicular melanocytes from autoimmune attacks.
February 2025 in “Biochemistry” This review summarizes the potential therapeutic applications of stem cells in dermatology, emphasizing their role in restorative and regenerative treatments through injections, topical applications, and scaffolds, supported by advancements in laboratory processes and quality control.
November 2024 in “Journal of Cosmetic Dermatology” Regenerative medicine is effective and safe for treating vitiligo.
260 citations
,
January 2020 in “Nature” Stress can cause hair to turn gray by depleting stem cells.
17 citations
,
January 2019 in “Annals of Dermatology” This study found that higher serum CXCL10 levels may predict the progression of non-segmental vitiligo, especially in patients also suffering from autoimmune thyroid disease and/or alopecia areata.
10 citations
,
September 2021 in “International Journal of Nanomedicine” This review explores the potential diagnostic and therapeutic applications of extracellular vesicles in treating various skin conditions but reports no new clinical study results.
6 citations
,
August 2024 in “BMC Ophthalmology” This study identified multiple genetic variants in Pakistani families with oculocutaneous albinism, including two novel variants, enhancing understanding of its genetic basis and aiding better management and counseling.
June 2025 in “IntechOpen eBooks” This chapter highlights the potential of exosomes as innovative agents in cosmetic dermatology, noting their ability to promote skin rejuvenation and target issues like wrinkles, photoaging, and hair loss.